Amicus Therapeutics (FOLD) falls 25% premarket as the company holds a conference call to discuss...


Amicus Therapeutics (FOLD) falls 25% premarket as the company holds a conference call to discuss the regulatory strategy for its Fabry disease treatment migalastat HCL. FOLD says it plans to incorporate information from three trials in an NDA: Trial 011 (top-line data expected in Q4), trial 012 (top-line data expected in H2 2014), and data from a long-term integrated Phase 2 study. An FDA meeting to discuss Fabry Monotherapy's approval pathway is now expected in H2 2014. (webcast)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs